BMS 184698
Latest Information Update: 18 Jan 2008
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Antihypertensives
- Mechanism of Action Angiotensin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 18 Jan 2004 Discontinued - Preclinical for Hypertension in USA (unspecified route)
- 10 Jul 1998 No-Development-Reported for Hypertension in USA (Unknown route)
- 19 Apr 1995 New profile